Synaptic Pharmaceutical Corporation

H. Lundbeck A/s

John E DeLeon

Mohammad R Marzabadi

John M Wetzel

Yu Jiang

Kai Lu

Chien-An Chen

Charles Gluchowski

Dhanapalan Nagarathnam

Stewart Alwyn Noble

Bharat Lagu

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

Substituted anilinic piperidines as MCH selective antagonists

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof

Growing community of inventors

North Bergen, NJ, United States of America

John E DeLeon